Skip to main content
Mersana Therapeutics, Inc. logo

Mersana Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRSN ISIN · US59045L1061 LEI · 529900VWD5VDZ7PVOS22 US Manufacturing
Filings indexed 700 across all filing types
Latest filing 2023-09-07 Director's Dealing
Country US United States of America
Listing US MRSN

About Mersana Therapeutics, Inc.

https://www.mersana.com/

Mersana Therapeutics, Inc. is a clinical-stage company focused on discovering and developing life-changing antibody-drug conjugates (ADCs) for patients fighting cancer. The company utilizes its proprietary and differentiated ADC platforms, which incorporate both cytotoxic and immunostimulatory payloads, to develop its pipeline. These platforms are designed to customize and optimize ADCs, aiming to overcome the limitations of first-generation technologies by improving efficacy and tolerability. Mersana is advancing a portfolio of ADC candidates to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2023-09-07 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-09-07 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-09-07 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 1, 2023, which is a current report used to announce major events that shareholders should know about. The content details the retirement of the CEO, appointment of a new CEO, separation agreements, and appointment of a new COO. These are changes in the company's board of directors and senior management. There is no financial data or earnings information, nor is it an annual or quarterly report. The document is not a proxy statement or voting results announcement. Therefore, the document fits the category of Board/Management Information (MANG). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement of a report publication.
2023-09-06 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-08-18 English
10-Q
Interim / Quarterly Report Q2 2023
2023-08-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.